CCTG Plenary Session announces speakers

CCTG is pleased to announce the the line up for one of the most informed events at the #CCT2024 Spring Meeting - The Plenary Session at Spring Meeting is on Friday May 3, 2024 from 4:30 - 5:30. Each of the talks highlight important CCTG trials and is open to registered participants attending the meeting in Toronto from May 3-5, 2024. This is a Royal College of Physicians and Surgeons of Canada accredited session. Thank you to the Co-Chairs: Dr Mariam Jafri, Dr Joe Pater, Dr Harriet Richardson for organizing this session.

Dr. Valsamo Anagnostou

4:30 – 4:45  

BR36: A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

Dr. Anagnostou is Associate Professor of Oncology, Director of the Thoracic Oncology Biorepository, Leader of Precision Oncology Analytics, and Co-Leader of the Molecular Tumour Board and the Thoracic Oncology Precision Medicine Centre of Excellence at the Sidney Kimmel Cancer Center at Johns Hopkins. She is a translational cancer investigator focusing on large-scale genomic and liquid biopsy analyses in human cancers. 

Dr. Kelly Davison

5:00 – 5:15  

HDC1: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age ≥ = 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Dr. Davison is an assistant professor in the Department of Medicine at McGill University, and a hematologist at the Royal Victoria Hospital, McGill University Health Centre where she is also a member of the stem cell transplant and immune effector cell program. Her clinical and research interests centre around the management of lymphoma and other lymphoproliferative disorders.

Dr. Penny Bradbury

4:45 – 5:00 

IND227: A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma – Phase III Results

Dr. Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre and Associate Professor, Department of Medicine, University of Toronto. Previously a Senior Investigator with CCTG for the Thoracic Oncology and Investigational New Drug Program, she is now Co-Chair of CCTG’s Thoracic Oncology Site Committee. Her research focuses on new therapies for the management of thoracic malignancies and clinical trial methodology.

Dr. Eileen Rakovitch

5:15 – 5:30

MAC18 (POSITIVE): A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive 

Dr. Rakovitch is Professor and Vice Chair of Clinical Affairs in the Department of Radiation Oncology at the University of Toronto. She is the L.C. Campbell Chair in Breast Cancer Research at the Sunnybrook Health Sciences Centre, Program Research Director of the Odette Cancer Program, and Co-Chair of CCTG’s Breast Site Committee. Her research focuses on improving the care and outcomes of women with an early form of breast cancer called ductal carcinoma in situ.